NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Forecast, Price & News

$1.18

-0.03 (-2.48%)

(As of 11:09 AM ET)

Compare

Today's Range: $1.13
▼
$1.21
50-Day Range: $0.98
▼
$1.53
52-Week Range: $0.91
▼
$15.20

Volume: 406,118 shs
Average Volume: 3.12 million shs
Market Capitalization: $112.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.32

Gossamer Bio MarketRank™ Forecast

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 520.2% Upside
$7.32 Price Target
Short Interest: Bearish
21.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$802,713 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.87) to ($1.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

202nd out of 981 stocks

Pharmaceutical Preparations Industry

88th out of 481 stocks

3.2

Analyst's Opinion

Consensus Rating
Gossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 5 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $7.32, Gossamer Bio has a forecasted upside of 520.2% from its current price of $1.18.
Amount of Analyst Coverage
Gossamer Bio has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
21.14% of the float of Gossamer Bio has been sold short.
Short Interest Ratio / Days to Cover
Gossamer Bio has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Gossamer Bio has recently decreased by 3.13%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Gossamer Bio does not currently pay a dividend.
Dividend Growth
Gossamer Bio does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Gossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Gossamer Bio is -0.67.

2.5

News and Social Media Coverage

News Sentiment
Gossamer Bio has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
Search Interest
Only 6 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gossamer Bio insiders have bought 5,268.60% more of their company's stock than they have sold. Specifically, they have bought $802,713.00 in company stock and sold $14,952.00 in company stock.
Percentage Held by Insiders
Only 9.50% of the stock of Gossamer Bio is held by insiders.
Percentage Held by Institutions
90.18% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gossamer Bio are expected to grow in the coming year, from ($1.87) to ($1.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gossamer Bio is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gossamer Bio is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gossamer Bio has a P/B Ratio of 9.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

May 27, 2023 | americanbankingnews.com

Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $6.35

May 18, 2023 | finance.yahoo.com

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 16, 2023 | americanbankingnews.com

HC Wainwright Comments on Gossamer Bio, Inc.'s Q2 2023 Earnings (NASDAQ:GOSS)

May 16, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) to Post Q2 2023 Earnings of ($0.48) Per Share, Wedbush Forecasts

May 13, 2023 | finance.yahoo.com

In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions

May 11, 2023 | seekingalpha.com

Gossamer Bio GAAP EPS of -$0.52 beats by $0.02

May 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Gossamer Bio (GOSS) Buy Recommendation

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 11, 2023 | seekingalpha.com

Gossamer Bio undergoes strategic restructuring; 25% of staff laid off

May 11, 2023 | markets.businessinsider.com

Gossamer Bio (GOSS) Receives a Buy from H.C. Wainwright

May 10, 2023 | markets.businessinsider.com

Wedbush Reaffirms Their Buy Rating on Gossamer Bio (GOSS)

May 9, 2023 | finance.yahoo.com

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

April 30, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.35 Average Target Price from Analysts

April 6, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) CFO Bryan Giraudo Purchases 55,000 Shares

April 5, 2023 | americanbankingnews.com

Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $7.14

April 4, 2023 | finance.yahoo.com

After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate

April 3, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

March 25, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Buys 440,500 Shares

March 25, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) to Post Q1 2023 Earnings of ($0.46) Per Share, HC Wainwright Forecasts

March 24, 2023 | americanbankingnews.com

Bryan Giraudo Buys 50,000 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) Stock

March 24, 2023 | americanbankingnews.com

Waage Christian Acquires 18,500 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) Stock

March 24, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Gossamer Bio, Inc. Increased by Analyst (NASDAQ:GOSS)

March 24, 2023 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Buys $173,743.49 in Stock

March 23, 2023 | americanbankingnews.com

Wedbush Reiterates "Outperform" Rating for Gossamer Bio (NASDAQ:GOSS)

March 22, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Gossamer Bio, Inc.'s FY2027 Earnings (NASDAQ:GOSS)

March 22, 2023 | americanbankingnews.com

Cantor Fitzgerald Weighs in on Gossamer Bio, Inc.'s FY2023 Earnings (NASDAQ:GOSS)

See More Headlines

GOSS Price History

30 days | 90 days | 365 days | Advanced Chart

GOSS Company Calendar

Last Earnings: 3/17/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GOSS
CUSIP: N/A
CIK: 1728117
Web: www.gossamerbio.com
Phone: (858) 684-1300
Fax: N/A
Employees: 185
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.32
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +504.8%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-229,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,755.82%
Return on Assets: -83.17%

Debt

Debt-to-Equity Ratio: 17.20
Current Ratio: 5.19
Quick Ratio: 5.19

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.13 per share
Price / Book: 9.31

Miscellaneous

Outstanding Shares: 95,440,000
Free Float: 86,377,000
Market Cap: $115.48 million
Optionable: Not Optionable
Beta: 1.20

Key Executives

Faheem Hasnain
Chairman, President & Chief Executive Officer

Bryan Giraudo
Chief Operating & Financial Officer

Christian Waage
EVP-Technical Operations & Administration

Richard Aranda
Chief Medical Officer

Laura Carter
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings or view top-rated stocks.
What is Gossamer Bio's stock price forecast for 2023?: 10 brokers have issued 12 month target prices for Gossamer Bio's stock. Their GOSS share price forecasts range from $1.50 to $17.00. On average, they anticipate the company's share price to reach $7.32 in the next twelve months. This suggests a possible upside of 504.8% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.
How have GOSS shares performed in 2023?: Gossamer Bio's stock was trading at $2.17 at the start of the year. Since then, GOSS shares have decreased by 44.2% and is now trading at $1.21.
View the best growth stocks for 2023 here.
When is Gossamer Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GOSS earnings forecast.
How were Gossamer Bio's earnings last quarter?: Gossamer Bio, Inc. (NASDAQ:GOSS) announced its quarterly earnings data on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.03.
What ETF holds Gossamer Bio's stock ?: WisdomTree BioRevolution Fund holds 2,078 shares of GOSS stock, representing 0.08% of its portfolio.
What other stocks do shareholders of Gossamer Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

When did Gossamer Bio IPO?: (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.
What is Gossamer Bio's stock symbol?: Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."
Who are Gossamer Bio's major shareholders?: Gossamer Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.02%), Palo Alto Investors LP (3.63%), Platinum Investment Management Ltd. (2.48%), Acadian Asset Management LLC (2.32%), Two Sigma Investments LP (1.96%) and Two Sigma Advisers LP (1.93%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.
How do I buy shares of Gossamer Bio?: Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gossamer Bio's stock price today?: One share of GOSS stock can currently be purchased for approximately $1.21.
How much money does Gossamer Bio make?: Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $115.48 million. The company earns $-229,380,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.
How many employees does Gossamer Bio have?: The company employs 185 workers across the globe.
How can I contact Gossamer Bio?: Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gossamer Bio (GOSS) Stock Forecast, Price & News

Gossamer Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Gossamer Bio (NASDAQ:GOSS) Stock

GOSS Stock News Headlines

GOSS Price History

GOSS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GOSS Stock - Frequently Asked Questions

Overall MarketRank^™